Abstract Cytogenetic aberrations are important prognostic factors in acute myeloid leukemia (AML). About 45 % of de novo adult AML and 20 % of pediatric AML lack cytogenetic abnormalities, so identification of predictive molecular markers might improve therapy. Mutation status of FLT3, NPM1 genes and gene expression levels of ERG, BAALC have been postulated as possible prognostic markers in pediatric AML with normal karyotype. Pretreatment blood samples from 47 cytogenetically normal AML patients were analysed for BAALC and ERG expression using real time RT-PCR. The patients were dichotomized at BAALC and ERG mean expression into low and high expression based on the median expression as cutoff. BAALC showed high expression in (24/47; 51.1 %) of patients and ERG high expression was detected in (22/ 47; 46.6 %). With follow-up for 1 year, patients with high BAALC and high ERG had inferior EFS (P = 0.001, P = 0.017 respectively), overall survival (P = 0.001, 0.08 respectively), and low rates of induction remission (P = 0.001, P = 0.0017 respectively) as compared to those with low expression. Also there was significant positive association between high expression of BAALC; ERG and FLT-ITD mutations (P = 0.016; P = 0.007 respectively). Multivariable analysis confirmed that high BAALC expression is an independent risk factor for EFS [HR for EFS 1.9(1.04-3.46) P = 0.037]; and OS [HR OS 1.55(1.7-3.36) P = 0.03]. In conclusion: Over expression of BAALC could predict adverse clinical outcome and may define important risk factor in cytogenetically normal pediatric AML.
Introduction
AML is a heterogeneous illness composed of subtypes, with blast-intrinsic genomic aberrations serving prominent roles in disease classification and clinical management. AML constitutes 15-20 % of childhood leukemia and has an overall survival (OS) of 70 %. The prognosis has improved over the past couple of decades through optimization of treatment protocols, in which identification of disease subgroups that are based on genetic markers has turned out to be essential [1] .
Approximately 45 % of adult AML patients and 20 % of pediatric AML patients are diagnosed with cytogenetically normal AML (CN-AML), which is currently classified and treated as a homogeneous intermediate-risk group. In order to refine risk stratification of pediatric CN-AML, it is important to study the underlying molecular aberrations [1] .
Among the genetic markers that has been previously studied in CN-AML patients are Fms-related tyrosine kinase 3 gene (FLT3) mutations [2] [3] [4] [5] , the nucleophosmin gene (NPM1) mutations [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , ERG [16, 17] and BAALC [18] [19] [20] [21] [22] expression levels. Although studies concerning the prognostic relevance of BAALC [18] and ERG expression [16, 17] in adult AML patients with CN AML become fully clear; the studies regarding their expression and prognostic impact in pediatric AML are few and of controversial results. Therefore, this study was planned in order to assess the prognostic impact of the expression of BAALC and ERG in children with de novo CN-AML patients in parallel with well established genetic markers which include NPM1 and FLT3.
Patient Samples and Treatment Protocols
Patient samples and treatment protocols: This study included 49 consecutive children with denovo AML attending hematology/Oncology unit, Mansoura Cancer Institute; between January 2010 and 2013, after signing written consent. This cohort of pediatric patients included was with a normal karyotype. None of these 49 patients had AML-M3 or Down syndrome.
Children patients age range between 2 and 15 years (median age 7 years). The diagnosis of AML was based on the presence of blast cell C20 % in bone marrow (BM) smear. FAB subtypes were (2M0, 7 M1, 13 M2, 15 M4, 8 M5, 2 M6). The diagnosis and FAB subtype were confirmed by immunophenotyping using (Coulter Epics XL Flowcytometer PN 42372238 B, Coulter Corporation, Miami, Florida 33196, USA) to confirm diagnosis (Cyt. MPO, CD 13, CD 33, CD 117) as a primary panel for myeloid lineage, (CD14, CD36, CD11b) for M4 and M5, (CD61, glycophorin A) for M6 and (CD41, CD42) for M7. The patients were observed for 12 months or until death. History taking and clinical examination for organomegaly were done for all patients. All patients had normal karyotypes on conventional cytogenetic examination of at least 20 metaphases. Patients were characterized at the molecular level with regard to FLT3ITD, NPM1 and were analyzed for BAALC and ERG expression. The study was performed in accordance to the Declaration of Helsinki, and parents and/or patients gave informed consent.
Therapy Protocol
The patients were treated according to standard protocols, most commonly 3 days of an anthracycline and 7 of ara-C (3 ? 7) [23] . Bone marrow aspiration was done between 21 and 28 days after initiation of chemotherapy. Consolidation comprised of three to four courses of high dose cytosine arabinoside(3 g/m 2 every 12 h on days 1,3 and 5;
total, 18 g/m 2 ) Following this, patients were followed up once every 3 months with clinical examination and complete counts for total period 12 months .
Cytogenetic and Molecular Genetic Analysis
Pretreatment samples from all patients were studied by G-banding analysis and fluorescence in situ hybridization (FISH). Conventional cytogenetic studies were performed using standard techniques, and chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature. To improve the accuracy of cytogenetic diagnosis, all specimens were also analyzed by FISH using a comprehensive DNA probe set allowing for the detection of the most relevant AML-associated genomic aberrations. Patients were classified as having normal cytogenetics on the basis of analysis of BM or PB metaphases; in most cases 20 metaphases were assessable.
RNA Extraction and Real-Time RT-PCR to Measure BAALC and ERG Expression Levels
Preparation of pretreatment blood samples and analysis of BAALC and ERG expression were performed as previously described 8-11. Briefly, total RNA extraction and isolation (QIAGEN) and complementary DNA was synthesized from total RNA. Quantitative real-time reversetranscription-polymerase chain reaction (RT-PCR) amplification of BAALC, and ERG was performed using standard curves. BAALC and ERG expression levels are reported as copy numbers normalized to ABL1 copy numbers.
Nucleotide Sequence of the Primers and Probes Used for Detection of BAALC and ERG Expression Levels
Detect FLT3/ITD and NPM1 Mutations DNA isolation and polymerase chain reaction Using QIA amp DNA blood mini kit (QIAGEN, USA) for DNA purification from whole blood and/or bone marrow aspiration.
To detect FLT3 and NPM1 genotype was determined as previously described [11] . Polymerase chain reaction (PCR) for exons 14 and 15 was performed on genomic DNA using published primer molecules for FLT3 and exon 12 for NPM1. For Gene scan analysis of the FLT3 mutant: wild-type ratio (FLT3 ratio) PCR primer FLT3 14F was labeled with 6-FAM (TIB MOLBIOL, Berlin, Germany).
Fragment Analysis Post-PCR Products Using Gene Mapper Software of FLT3 and NPM1
Gene Mapper analysis software automatically analyzes the data collected by ABI prism 310 Genetic Analyzer to size and quantitate DNA fragment. Fluorescently labeled PCR products are electrophoresed through an acrylamide containing polymer, POP4 (PE Applied Biosystem, USA), which is then analyzed using an ABI prism 310 Genetic Analyzer. The associated gene mapper software version 4.1 is then able to convert the information into an correspond to intensity of fluorescence detected. Electropherogram show fluorescence intensity as a function of fragment size or migration time. Each electropherogram represents a single injection. The expected peak size for the wild FLT3 PCR product is 330 bp. FLT-ITD fragment can be 18-108 bp larger than this. Only ITD positive cases are reported if the ITD represent at least 5 % of the peak area of FLT3 WT fragment. As regards wild NPM1, its product expected peak size is 287 bp, while NPM1 mutant is usually 4 bp lager.
Statistical Analysis and Definition of Clinical Endpoints
The statistical analysis of data was done by using excel program and SPSS version 16 (statistical package for social 
science). Qualitative data were described in the form of numbers and percentages. Quantitative data were described in the form of mean (±) standard deviation (SD). Statistical analysis were done by comparison between groups using v 2 test regarding qualitative data while quantitative nonparametric data comparison was performed using one way ANOVA and paired sample t test. The probability of being by chance (P value) was calculated for all parameters (P is significant if \or = 0.05 at confidence interval 95 %). The Event-free survival (EFS) and the OS were analyzed by Kaplan-Meier curve. OS is the time from diagnosis to last follow-up or death from any cause. EFS is the time from diagnosis until relapse.
Results
The patient's characteristics are shown in Table 1 . BAALC showed high expression in (23/47, 49.9 %) of patients and ERG high expression was detected in (22/47, 46.6 %). The incidence of gene mutations of FLT3-ITD and NPM1 were detected in 6 out of 47 (12.6 %), and in 5 out of 47 (10.6 %) of pediatric CN-AML patients respectively. Interrelation between NPM1 and FLT3-ITD mutations and ERG, BAALC expression revealed that there is significant positive association between high expression of BAALC and ERG and mutant FLT3-ITD, and negative association with mutant NPM1 (P \ 0.01 for all) ( Table 1) . Study the BAALC and ERG expression in relation to induction remission response revealed that AML patients with high expression of ERG and BAALC are associated with inferior remission induction rate as compared with those with low expression (P = 0.001, P = 0.0017 respectively) ( Table 2 ).
Univariate analysis including many prognostic variables including WBCs counts (\ = 50,000 vs. [50,000/cmm), FLT3-ITD mut vs wild type; NPM1 mut vs wild type; high expression of BAALC and ERG vs low expression of BAALC and ERG; and response to induction remission (poor vs., Good vs. non determined) revealed significant differences in all these parameters except NPM1 regarding EFS and OS (Table 3; Figs. 1a, b, 2a, b) .
The genetic markers that were significantly different in univariate analysis were tested in multivariate analysis in order to find the independent parameters regarding EFS and OS. The Cox regression analysis showed that high BAALC expression was the independent prognostic factor for EFS and OS in CN AML pediatric patients (Table 4) .
Discussion
Chromosomal abnormalities provide a powerful tool to stratify AML patients into different prognostic risk groups. Patients lacking cytogenetic aberrations, accounting for approximately 45 % of newly diagnosed de novo AML cases, are contained in an intermediate risk group. For these patients the identification of novel molecular markers is necessary to overcome the limitations of current risk assessment and to design new risk-adapted treatment strategies [24] . Table 2 BAALC and ERG expression in relation to induction response
High expression (n = 23)
High expression (n = 22)
Good response defined as \5 % BM blasts after induction therapy. Low and high expression defined as above and below the median value, respectively Response to induction Poor 13 X 2 = 86.8, P = 0.001
In the present study the high expression of BAALC and ERG were detected in 23 out of 47 (51.1 %) and in 22 out of 47 (46.8 %) of patients respectively. This finding is not in accordance with that reported by Eid et al. [25] , they stated that high expression of BAALC and ERG were found in 70 and 33.3 % of patients respectively. In addition Eid et al. [25] stated that the high BAALC and ERG expression was correlated to both percentage of blast cells in the blood and BM, but did not associated with other clinical parameters of patients and high ERG expression was associated with higher white cell counts.
Our results indicated that the incidence of gene mutations of FLT3-ITD and NPM1 were detected in 6 out of 47 (12.6 %), and in 5 out of 47 (10.6 %) of pediatric CN-AML patients respectively. Significant association between high BALLC and ERG expressions and the presence of FLT3-ITD mutations were detected. Near findings were reported by Krstovski et al. [26] who detected FLT3 mutations in 4/42 (9.5 %) and NPM1 mutations in 1/37 (2.7 %). Fig. 1 a EFS for patients with high BAALC expression was significantly inferior than patients with low BAALC expression (P = 0.001). The event free survival was calculated by months. b)OS for patients with high BAALC expression was significantly inferior than patients with low BAALC expression (P = 0.001). The overall survival was calculated by months Fig. 2 a EFS for patients with high ERG expression was significantly inferior to patients with low ERG (P = 0.017). The event free survival was calculated by months. b Overall Survival for patients with high ERG expression was significantly inferior to patients with low ERG (P = 0.008). The overall survival was calculated by months
In the current study high BAALC and ERG expressions were significantly associated with poor response to induction chemotherapy in CN-AML children. Similar finding was reported by Eid et al. [25] . Also, high BAALC and ERG expression had inferior EFS, and OS. These findings are in parallel with that reported by Eid et al. [25] . Univariate analysis revealed that High ERG and BAALC expression; showed a significant association with inferior EFS as well as shorter OS.
Based on in vitro culture studies observation Tanner et al. [27] suggested that the expression of BAALC is stage specific and postulate that BAALC represents a novel marker of an early progenitor cell common to the myeloid, lymphoid, and erythroid pathways. Moreover, Baladus et al. [28] stated that BAALC over expression is clearly nonrandom among AML French-American-British subtypes and AML cytogenetic groups, pointing to a role of BAALC in the leukemic phenotype. Its association with an adverse prognosis in AML is a further indication of it having a role in one or more processes that characterize these blasts.
In multivariate analysis, FLT3-ITD and high BAALC expression remained as prognostic factors for adverse EFS and OS. In Cox regression analysis high BAALC expression is independent prognostic markers for both EFS and OS. High ERG and BAALC expression showed a significant association with inferior EFS. These findings are parallel to that reported by Eid et al. [25] and Hovland et al. [24] Haferlach et al. [29] . On the other hand, high BAALC and ERG expression levels did not have independent prognostic significance in pediatric AML cohort or in the CN-AML subgroup specifically in the study done by Hermkens et al. [30] . This might be related to ethnic origin of the patients studied.
Expression levels of ERG, and BAALC were significantly associated with each other. Schwind et al. [31] believed that measuring BAALC and ERG expression at diagnosis seems to provide more prognostic information with regard to survival than NPM1 mutational status alone. Moreover, they stated that patients with high BAALC expression had worse outcome irrespective of their NPM1 mutational status. Thus, the measurement and evaluation the pretreatment expression levels of BAALC and ERG in individual patients could be included as diagnostic testing for a more accurate risk stratification of older CN-AML patients.
In conclusion, we show that high BAALC expression is adverse prognostic marker for induction of remission achievement, EFS and OS in CN pediatric AML.
The number of patients enrolled was small, and during statistical analysis we found that there is a need to subclassify the AML patient's harbored mutations in FLT3-ITD and NPM1 to make association with degree of expression with BAALC and ERG. This led to decrease the statistical power of some analysis. So, we suggest extending the study to include larger group. Another limitation of the study is that the follow up period is short for AML, though effect is significant, however a longer follow up will show if these patients with low ERG will also relapse or die. 
